Trial Profile
A phase 3 study of leronlimab (PRO 140) in combination with remdesivir for the treatment of COVID-19
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 30 Mar 2022 Status changed from planning to suspended, according to a CytoDyn media release.
- 30 Mar 2022 According to a CytoDyn media release, the U.S. Food and Drug Administration (FDA) a full clinical hold on leronlimab its COVID-19 program in the United States. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved.
- 21 May 2020 New trial record